We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Breast Ultrasound Volume Calculator Accurately Monitors Cancer Treatment

By MedImaging International staff writers
Posted on 26 Sep 2022
Print article
Image: QTscan delivers safe, accurate monitoring of breast cancer treatment (Photo courtesy of QT Imaging)
Image: QTscan delivers safe, accurate monitoring of breast cancer treatment (Photo courtesy of QT Imaging)

Conventional breast imaging modalities, such as mammography, face tremendous challenges when imaging dense breast tissue, which puts women with dense breasts – nearly half the female population – at an immediate disadvantage. This is because cancer can appear similar to regular breast tissue and if there is a lot of breast tissue (such as in the case of dense breasts), the cancer can ‘hide’. Now, a new technology with the ability to image through dense breasts calculates the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer.

Unlike traditional breast imaging modalities, the QTscan from QT Imaging, Inc. (Novato, CA, USA) does not require radiation, injection, or compression, and is highly accurate (+ 0.2%), allowing earlier and more frequent monitoring for women undergoing non-surgical breast cancer treatments such as adjuvant chemotherapy, radiation therapy, cryotherapy, and hormone or selective hormone receptor modulation treatments. The U.S. Food and Drug Administration (FDA) has granted QT Imaging 510(K) clearance to calculate the FGV of the breast and the ratio of FGV to TGV. No other ultrasound-based breast imaging modality is cleared by the FDA to quantify fibroglandular volume.

The proposed indications for use, as designated by the FDA as breakthrough, are:

"The QT Scanner 2000 Model A is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The QT Scanner 2000 Model A software also calculates the breast fibroglandular tissue volume (FGV) value and the ratio of FGV to total breast volume (TBV) value as determined from reflection-mode and transmission-mode ultrasound images of a patient's breast. The device is not intended to be used as a replacement for screening mammography."

"The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy. The FGV tool will allow this assessment to be made early and in follow-up to maximize treatment benefit, which is an exciting development for breast care patients," said Dr. Elaine Iuanow, a Breast Imaging specialist and medical consultant for QT Imaging.

"We are excited to expand the tools available using low frequency transmitted ultrasound volography to serve women, especially those with dense breasts, providing an imaging option that is safe, comfortable, and effective," said Dr. John Klock, CEO, Chief Medical Officer and Founder of QT Imaging, Inc.

Related Links:
QT Imaging, Inc. 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
PACS Workstation
CHILI Web Viewer
New
Ultrasound Doppler System
Doppler BT-200
New
Breast Imaging Workstation
SecurView

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.